What is the appropriate medication regimen for a 25‑week‑gestation pregnant woman presenting with an allergy?

Treatment for Allergic Conditions at 25 Weeks Gestation

For a pregnant woman at 25 weeks gestation with allergies, use second-generation antihistamines (cetirizine or loratadine) as first-line therapy, combined with saline nasal rinses and intranasal corticosteroid sprays for optimal symptom control while ensuring fetal safety.

First-Line Pharmacologic Treatment

Antihistamines

• Second-generation antihistamines are the preferred choice at 25 weeks gestation 1
• Cetirizine and loratadine have the strongest safety data, with evidence from over 186,000 pregnancy exposures showing no increased risk of major congenital malformations, spontaneous abortions, or premature births 2, 3, 4
• First-generation antihistamines (like diphenhydramine, chlorpheniramine) should be avoided due to sedative and anticholinergic properties that can affect both mother and fetus 1

Intranasal Corticosteroids

• Topical corticosteroid nasal sprays are safe and effective during pregnancy 1
• Budesonide is specifically recommended as the intranasal corticosteroid of choice if needed 3
• These provide local anti-inflammatory effects with minimal systemic absorption

Non-Pharmacologic Measures

• Saline nasal rinses should be used routinely as they are completely safe and effective for symptom control 1
• Environmental allergen avoidance strategies should be implemented

Medications to Avoid

Absolutely Contraindicated

• Oral decongestants (pseudoephedrine, phenylephrine) - increase risk of fetal gastroschisis and maternal hypertension 1
• Intranasal antihistamines - insufficient safety data 3
• Aspirin and NSAIDs - Category D; risk of premature ductus arteriosus closure, intrauterine growth restriction, and perinatal mortality 1

Use with Caution

• Anti-leukotrienes (montelukast) - avoid for routine allergy treatment, but may continue if already being used for recalcitrant asthma with prior good response 1

Special Considerations for Immunotherapy

• If already on allergen immunotherapy: Continue at current maintenance dose 1
• Do NOT initiate or increase doses during pregnancy due to anaphylaxis risk 1
• Sublingual immunotherapy is contraindicated during pregnancy 1

Critical Safety Points

Anaphylaxis Preparedness

At 25 weeks gestation, the fetus is viable but premature. If the patient has a history of severe allergic reactions:

• Intramuscular epinephrine remains first-line treatment for anaphylaxis during pregnancy 5, 6
• Delayed epinephrine administration poses greater risk to both mother and fetus than the medication itself
• Ensure patient has epinephrine auto-injector if indicated

Monitoring Considerations

• The second trimester (which includes 25 weeks) shows 17-22% suppression of eosinophils due to hormonal changes 2
• Pregnancy may alter allergic disease severity - symptoms can improve, worsen, or remain stable
• Pharmacokinetic changes in pregnancy (20-40% reduction in plasma protein concentrations) may affect drug levels, but cetirizine and loratadine maintain favorable safety profiles 2

Practical Treatment Algorithm

1. Start with saline nasal rinses (2-3 times daily)
2. Add cetirizine 10mg daily OR loratadine 10mg daily for persistent symptoms
3. Add intranasal corticosteroid spray (budesonide preferred) if symptoms inadequately controlled
4. Avoid all oral decongestants regardless of symptom severity
5. Continue existing allergen immunotherapy at maintenance dose only (do not escalate)

This approach prioritizes both maternal quality of life and fetal safety, with the strongest evidence supporting second-generation antihistamines combined with topical therapies 1, 2, 3.